newsfilter
← Latest News
GlobeNewswire·

Neoleukin Therapeutics Announces Initiation of Phase 1 NL-201 Trial

SEATTLE, May 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced dosing the first pati